Abstract: The present invention describes an improved industrial process for crystallizing out polymorph ‘Form I’ of (+) clopidogrel hydrogen sulphate (also called clopidogrel bisulphate) in) from either a Type-1 solvent or liquid characterized by comprising two or more functional groups or their mixtures thereof; or a Type-II solvent and/or solvent mixture selected from the group of methyl ethyl ketone, cyclopentylmethyl ether, dipropylglycolether, dibutylglycol ether, propylmethyl cellosolve, butylmethylcellosolve, propylethylellosolve, butylethylcellosolve or their cross combinations in a reproducible manner without detectable contamination of polymorph designated as ‘Form II’. The invention also discloses improvements in the preparation of clopidogrel free base and process for recovery and recycling of resolving agent camphor sulphonic acid.

Abstract: A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.

Abstract: The present invention describes an improved industrial process for crystallizing polymorph Form I of (+) clopidogrel hydrogen sulphate (also called clopidogrel bisulphate) in either a Type-I solvent or a Type-II. Type I solvent is an organic solvent containing two or more functional groups with a proviso that at least one functional group is different from the other(s). The Type II solvent is selected from methyl ethyl ketone, cyclopentylmethyl ether, dipropylglycolether, dibutylglycol ether, propylmethyl cellosolve, butylmethylcellosolve, propylethylellosolve, butylethylcellosolve or their cross combinations. The process produces Form I in a reproducible manner without detectable contamination of polymorph designated as Form II.

Abstract: The present invention relates to a process for preparation of sulfonyl urea compounds in high conversion rates and purity. More specifically, this invention relates to a process for manufacture of sulfonyl urea class of anti-diabetic pharmaceutical drugs in higher purity and yield. The process may effectively and economically be used to produce anti-diabetic drugs, such as glimepiride, glipizide, gliclazide, glibenclamide, glibornuride, and glisoxepide.

Abstract: A method and system for testing a software application. A description of a test suite for testing the software application being tested (ABT) is inserted into a test database. The ABT is invokes multiple external software applications during execution of a test script of the test suite. Each external application invoked by the ABT is replaced by a corresponding simulator during execution of the test script. Output data to be returned to the ABT by each invoked simulator is inserted into the test database, after which each test script of the test suite is executed. The executing includes: sending a request, by the ABT to each simulator invoked in each test script, for requested data; and receiving, by the ABT, the requested data from each simulator invoked in each test script. The received requested data includes the output data that had been inserted into the test database.

Abstract: A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.

Abstract: Disclosed herein is a process for preparation of carvedilol substantially free from its bis-impurity comprises the reaction of 4-(2,3-epoxypropoxy)carbazole and 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent media; followed by isolation of carvediol from the reaction mass as an acid addition salt and subsequent conversion into pure carvedilol.